Last reviewed · How we verify

NCT00325637

A Multi-Center, Double Blind, Randomized and Non-Inferiority Clinical Study of Cilnidipine to Compare the Effects on Cerebral Blood Flow With Losartan in Patients With Ischemic Stroke Hypertension

Completed Phase 3 Last updated 11 December 2008
What this trial tests

Phase 3 trial testing cilnidipine in Hypertension in 250 participants. Completed in 1 August 2007.

Timeline
1 January 2005
Primary endpoint
1 July 2007
1 August 2007

Quick facts

Lead sponsorBoryung Pharmaceutical Co., Ltd
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment250
Start date1 January 2005
Primary completion1 July 2007
Estimated completion1 August 2007
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Boryung Pharmaceutical Co., Ltd — full company profile →

Who can join

Adults 35 to 80, any sex, with Hypertension or Stroke. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to compare the effect of cilnidipine (a calcium channel blocker) and losartan (an angiotensin II receptor blocker) on cerebral blood flow (CBF) and blood pressure in hypertensive patients with a previous ischemic stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Boryung Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00325637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing